These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 31396809)

  • 1. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization.
    El Khoury A; Patel C; Huang A; Wang L; Bashyal R
    Curr Med Res Opin; 2019 Dec; 35(12):2159-2168. PubMed ID: 31366251
    [No Abstract]   [Full Text] [Related]  

  • 3. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
    DerSarkissian M; Lefebvre P; Joshi K; Brown B; Lafeuille MH; Bhak RH; Hellstern M; Bobbili P; Shiner B; El Khoury AC; Young-Xu Y
    Clin Ther; 2018 Sep; 40(9):1496-1508. PubMed ID: 30145029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.
    Emond B; El Khoury AC; Patel C; Pilon D; Morrison L; Zhdanava M; Lefebvre P; Tandon N; Joshi K
    Curr Med Res Opin; 2019 Mar; 35(3):407-416. PubMed ID: 30556739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
    Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
    Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
    Joshi K; Lafeuille MH; Brown B; Wynant W; Emond B; Lefebvre P; Tandon N
    Curr Med Res Opin; 2017 Oct; 33(10):1763-1772. PubMed ID: 28741387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia.
    El Khoury AC; Patel C; Mavros P; Huang A; Wang L; Bashyal R
    Neuropsychiatr Dis Treat; 2021; 17():3159-3170. PubMed ID: 34703236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
    Basu A; Benson C; Alphs L
    J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
    Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
    J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
    Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate.
    Patel C; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Tandon N; El Khoury AC
    Drugs Real World Outcomes; 2020 Mar; 7(1):19-29. PubMed ID: 31786737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate.
    Emond B; Joshi K; Khoury ACE; Lafeuille MH; Pilon D; Tandon N; Romdhani H; Lefebvre P
    Pharmacoecon Open; 2019 Jun; 3(2):177-188. PubMed ID: 30088229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
    Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
    Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis.
    Patel C; Khoury AE; Huang A; Wang L; Bashyal R
    Curr Ther Res Clin Exp; 2020; 92():100587. PubMed ID: 32714469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
    Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
    BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting.
    Cirnigliaro G; Battini V; Cafaro R; Mosini G; Vanzetto S; Prodi T; Macellaro M; Leuzzi R; Conti D; Carnovale C; Dell'Osso B
    Expert Rev Neurother; 2023; 23(11):1031-1039. PubMed ID: 37750003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
    Wang GH; Svensson M; Shao H; Vouri SM; Park H
    J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.